Evaluating liver damage in patients with anorexia nervosa using blood tests
BILAN: Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood BIomarker ANaLysis
This study is testing how blood tests can help doctors understand liver damage in people with anorexia nervosa who are 15 years or older.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 15 Years to 99 Years |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Trial ID | NCT06262165 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between blood biomarkers and liver damage in patients diagnosed with anorexia nervosa. It focuses on identifying hepatic cytolysis, indicated by elevated levels of AST and/or ALT in the blood. The study will involve patients over 15 years old who are admitted to Nantes University Hospital and meet specific diagnostic criteria. By analyzing these biomarkers, the study seeks to enhance understanding of liver health in individuals with eating disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals over 15 years old diagnosed with anorexia nervosa or other restricted eating disorders.
Not a fit: Patients with chronic liver diseases, excessive alcohol consumption, or those on specific medications that induce fatty liver disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of liver health in patients with anorexia nervosa.
How similar studies have performed: While studies on liver health in anorexia nervosa are limited, the approach of using blood biomarkers for evaluation has shown promise in related research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Patient over 15 years old * Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Admission to Nantes University Hospital. Exclusion Criteria : * Chronic active viral hepatitis * Hemochromatosis * Other genetic, autoimmune. * Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women) * Pregnant, parturient or breast-feeding women, persons deprived of liberty, adults under legal protection or unable to express their consent, persons not affiliated or not beneficiaries of a social security scheme, persons under guardianship or curators
Where this trial is running
Nantes, Loire-Atlantique
- Nantes University Hospital — Nantes, Loire-Atlantique, France (Recruiting)
Study contacts
- Study coordinator: Sarra SMATI-GRANGEON, PH
- Email: sarra.grangeon@chu-nantes.fr
- Phone: 33 2 53 48 27 01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.